ARTICLEhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/3/article-p257.xmlIndustry “Rewrites” of NCCN Guidelines2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/3/article-p257.pdf2026-04-18Industry “Rewrites” of NCCN Guidelineshttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/3/article-pxxviii.xmlAdjuvant Chemotherapy Regimens for Breast Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/3/article-pxxviii.pdf2026-04-18Adjuvant Chemotherapy Regimens for Breast Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/3/article-pxxiv.xmlOncology Research Program2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/3/article-pxxiv.pdf2026-04-18Oncology Research Programhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/3/article-pxx.xmlNCCN News2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/3/article-pxx.pdf2026-04-18NCCN Newshttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/3/article-p280.xmlAcute Myeloid Leukemia2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/3/article-p280.pdf2026-04-18Acute Myeloid Leukemiahttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/3/article-p268.xmlDevelopment and Validation of 11 Symptom Indexes to Evaluate Response to Chemotherapy for Advanced Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/3/article-p268.pdf2026-04-18Development and Validation of 11 Symptom Indexes to Evaluate Response to Chemotherapy for Advanced Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/3/article-p261.xmlIs the Battle Over Bevacizumab Coverage Looming?2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/3/article-p261.pdf2026-04-18Is the Battle Over Bevacizumab Coverage Looming?https://harbor.dev.pubfactory.com/view/journals/jnccn/9/3/article-p265.xmlAccess to and Appropriateness of Cancer Care: Who Decides?2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/3/article-p265.pdf2026-04-18Access to and Appropriateness of Cancer Care: Who Decides?https://harbor.dev.pubfactory.com/view/journals/jnccn/9/3/article-p337.xmlTreatment of Acute Promyelocytic Leukemia for Older Patients2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/3/article-p337.pdf2026-04-18Treatment of Acute Promyelocytic Leukemia for Older Patientshttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/3/article-p319.xmlIdentifying Older Patients With Acute Myeloid Leukemia Who May Be Candidates for Reduced-Intensity Hematopoietic Cell Transplantation2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/3/article-p319.pdf2026-04-18Identifying Older Patients With Acute Myeloid Leukemia Who May Be Candidates for Reduced-Intensity Hematopoietic Cell Transplantationhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/3/article-p331.xmlNovel Agents for the Treatment of Acute Myeloid Leukemia in the Older Patient2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/3/article-p331.pdf2026-04-18Novel Agents for the Treatment of Acute Myeloid Leukemia in the Older Patient